A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

612

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Endometrial Cancer

Interventions

DRUG: REGN5668
DRUG: Cemiplimab
DRUG: Ubamatamab
DRUG: Sarilumab
DRUG: Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

Sponsor

Regeneron Pharmaceuticals